8-K: Better Choice Company Announces Progress on SRx Health Acquisition, Projecting $270 Million in Combined Revenue

Better Choice Company is progressing with its acquisition of SRx Health Solutions, anticipating a combined revenue of $270 million and $10 million in EBITDA by 2025.

Summary

• Better Choice Company is moving forward with its acquisition of SRx Health Solutions in an all-stock transaction valued at approximately $125 million.
• The combined company is expected to become a leading global health and wellness provider for pets, people, and families.
• Projections for 2025 include combined revenue of over $270 million and EBITDA of over $10 million.
• Better Choice's Halo brand generated approximately $49 million in gross sales in 2023, with half from e-commerce and 28% from international sales.
• SRx Health generated approximately CAD$180 million in revenue and positive adjusted EBITDA in 2023.
• The transaction is expected to close in late Q4 2024 or early Q1 2025.
• The combined companies have generated $235 million in revenue for the trailing twelve months, increasing approximately 25% quarter-over-quarter.
• Immediate cost savings of approximately $1.7 million annually are expected, with potential for further savings.
• Better Choice plans to expand into veterinary medicine in 2025 with its new initiative Better Pet Rx.
• The pro forma fully diluted shares outstanding is 22,911,334 shares, with insiders owning approximately 75% of the outstanding shares.
• Net tangible book value is $4.07 per share and net current asset value per share is $3.94.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the strategic acquisition, projected growth, and cost savings. The forward-looking statements are optimistic, and the management commentary is confident. However, there are some risks and uncertainties mentioned, which temper the overall sentiment slightly.

Positives

• The acquisition of SRx Health is expected to create a leading global health and wellness company.
• The combined company is projected to have significant revenue and EBITDA growth in 2025.
• Better Choice's Halo brand is showing strong sales growth, particularly in e-commerce and international markets.
• SRx Health has a strong existing business with significant revenue and positive adjusted EBITDA.
• The merger is expected to generate cost savings and operational efficiencies.
• There are opportunities for expansion into new markets and verticals, such as veterinary medicine.
• The company has a strong insider ownership of approximately 75%.

Negatives

• The pro forma financial information is based on management's assumptions and is not audited.
• The financial statement impact upon conversion from IFRS to GAAP is still being analyzed.
• The transaction is subject to shareholder approval.

Risks

• The company's ability to obtain additional capital in the future is a risk.
• The proposed transaction with SRx is subject to risks and uncertainties.
• General economic factors and competition in the industry could impact results.
• The company's ability to successfully integrate SRx Health is a risk.
• The pro forma financial information is based on management's assumptions and is not audited.

Future Outlook

The combined company expects to be a leading global health and wellness company by 2025, with significant revenue and EBITDA growth, expansion into new markets, and cost savings.

Management Comments

• Michael Young, Chairman of Better Choice Company, stated that the acquisition of SRx Health will position Better Choice as a leading global health and wellness company.
• Management believes the combination will generate significant cash flow, operational efficiencies, and cost savings.
• Management expects the transaction to close in late Q4 of this year or early Q1 of 2025.

Industry Context

This announcement reflects a trend of consolidation in the health and wellness industry, with companies seeking to expand their product offerings and market reach through strategic acquisitions. The move into veterinary medicine also aligns with the growing pet humanization trend.

Comparison to Industry Standards

• The projected combined revenue of $270 million would place the company in a competitive position within the mid-sized health and wellness sector.
• The expansion into veterinary medicine with Better Pet Rx is similar to moves by other pet food companies to diversify their offerings.
• The focus on specialty pharmacy by SRx Health is comparable to other specialty pharmacy networks in North America.
• The projected EBITDA of $10 million is a key metric that will be compared to industry peers to assess profitability.

Stakeholder Impact

• Shareholders are expected to benefit from the increased value of the combined company.
• Employees may experience changes due to the integration of the two companies.
• Customers are expected to have access to a broader range of health and wellness products and services.
• Suppliers may see increased demand due to the expanded operations.
• Creditors may see increased stability due to the larger and more diversified business.

Next Steps

• The company will prepare a proxy statement for stockholders to vote on the transaction.
• The transaction is expected to close in late Q4 2024 or early Q1 2025.
• The company plans to expand into veterinary medicine in 2025 with Better Pet Rx.
• The company will continue to integrate the two businesses and seek further cost savings.

Key Dates

Keywords

acquisition, SRx Health, pet health, wellness, revenue, EBITDA, Halo, veterinary medicine, merger, pharmacy